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To test the ability of endoluminal stents to prevent saphe- 
nous vein graft restenosis after balloon angioplasty, 13 
patients with angina and previous coronary bypass surgery 
underwent implantation of one or more stents into 14 
stenosed grafts. Implantation was technically successful in 
all cases and there were no major in-hospital complications. 
During a median follow-up interval of 7 months (range 2 to 
26), 10 patients (77%) underwent follow-up angiography. 
Seven patients remained asymptomatic or in improved 
condition without further intervention; three patients had 
further angioplasty with stent implantation for a new 
stenosis in the same graft. Two patients (20%) developed 
Recurrent angina due to graft attrition after coronary artery 
bypass surgery often constitutes a difficult therapeutic prob- 
lem. Reoperation is associated with increased morbidity and 
mortality (1,2) and long-term results have been reported to 
be inferior to those of the first intervention (3). Balloon 
angioplasty is often an effective alternative to surgery in 
such a situation; it has a low rate of complications (4-6) and 
initial success rates vary from 80% to 96% depending on 
location of the lesion (6). However, the restenosis rate is 
high: 26% to 43% in the larger series (5-7) and even higher 
(61%) when the lesion is situated in the graft body rather 
than at the proximal or distal site of anastomosis (4-6). 
Because of this well documented high restenosis rate, on 
the one hand, and the potential risks of a second surgical 
intervention, on the other, it appears desirable to improve 
the long-term results of balloon angioplasty. We report our 
initial experience with stent implantation after balloon angio- 
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within-stent restenosis. There was one death from progres- 
sive congestive heart failure 7 months after implantation. 
No patient had a myocardial infarction or needed surgical 
revascularization during the follow-up period. 
In selected cases, stem implantation appears to be a 
promising new technique that may decrease the incidence of 
restenosis after balloon angioplasty in venous bypass grafts. 
The rate of complications is low. Further experience and 
longer follow-up will be needed before definite recommen- 
dations can be made about its use. 
(J Am Co11 Cardiol1989;13:1085-91) 




Study patients. Between April 1986 and May 1988, 13 
patients underwent implantation of one or more stents into 
14 saphenous vein bypass grafts. Ten patients had under- 
gone one coronary bypass operation, and the remaining 
three had had two separate operations. The last surgical 
revascularization procedure had been done a median of 5 
years earlier (range 1 to 16), with a median of three grafts per 
patient (range two to four). At the time of stenting, a median 
of two grafts (range one to three) were occluded or stenosed. 
There were 11 men and 2 women with a mean age of 63 2 
7 years. All had stenosis of at least one coronary bypass 
graft. multivessel disease of native coronary arteries and 
angina1 symptoms, either stable exercise-induced (12 pa- 
tients) or unstable symptoms at rest (1 patient). Left ventric- 
ular ejection fraction was only moderately impaired for most 
patients (median 57%, range 40% to 68%). Five patients 
were treated for lesions that had recurred after previous 
balloon angioplasty (median of two previous angioplasty 
procedures, range one to four). Some of the data concerning 
the first three patients in this series have been previously 
reported (8). Although stent implantation was performed 
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with surgery available on standby in all cases, two patients 
had a clear contraindication to elective coronary bypass 
reoperation (one with previous severe mediastinitis and one 
had no more veins available for grafting in either legs or 
arms); and seven patients had a relative contraindication to 
surgery (two previous bypass operations in three and poor 
general condition or associated disease in four). 
The vein graft lesions. The target lesions were situated in 
a saphenous graft in all cases: three to the left anterior 
descending coronary artery, seven to the lateral circumflex 
coronary artery or a marginal branch and four to the right 
coronary artery. One lesion involved the proximal graft 
implantation site on the aorta and all others were situated in 
the body of the graft. Lesion severity was assessed from 
diameter reduction in at least two perpendicular angio- 
graphic views. Only lesions that reduced the mean luminal 
diameter by 270% were considered for treatment. Initial 
success was defined as the absence of any residual stenosis 
within the stented segment after implantation, and restenosis 
was defined as a diameter reduction of ~50% within the 
stented segment at follow-up angiography. 
Selection of patients. Criteria for selection were 1) angina1 
symptoms not controlled on medical therapy, 2) graft lesion 
technically amenable to balloon angioplasty (stenosis or 
restenosis), and 3) informed consent obtained. 
Patients were excluded if 1) the bypass graft was oc- 
cluded; 2) the angioplasty catheter failed to cross the lesion; 
3) the lesion was considered unsuitable for stenting (i.e., 
there we.re important difference in diameter between the 
proximal and distal portion of the vessel segment to be 
stented, poor distal runoff, location of the lesion at the distal 
anastomosis with both anterograde and retrograde flow in 
the recipient coronary artery); and 4) informed consent was 
not obtained. 
During the study period, five patients underwent vein 
graft balloon angioplasty but did not receive a stent. The 
reasons for not stenting the grafts were unsuitable anatomy 
in three cases, failed angioplasty (lesion not crossed with the 
balloon) in one case and angioplasty for an occluded graft in 
one case. 
Stent. The stent (Medinvent), which has been described 
previously (8), is composed of a stainless steel alloy and has 
a self-expanding mesh design. It is flexible along its long 
axis; its length for coronary graft implants varies between 15 
and 29 mm and its diameter in the fully expanded state is 
typically 3 to 6 mm. For any given lesion a stent is selected 
with a fully expanded diameter approximately 15% larger 
than the estimated normal lumen of the recipient graft so that 
it will be stable once positioned and exert a residual radial 
pressure on the vessel wall. Before implantation, a doubled- 
over membrane maintains the stent constrained and elon- 
gated on the delivery system. This is introduced into the 
coronary artery through a standard 8F or 9F guiding catheter 
over an exchange guide wire. Retraction of the membrane 
Figure 1. Diagram of stent implantation. Top, The stem is con- 
strained and elongated on the delivery system. Middle, The doubled- 
over membrane has been inflated and partially retracted. The stent 
is half-released and its distal extremity is expanded. Bottom, The 
stent is completely released into the recipient vessel, the membrane 
is fully retracted and the introducing device is free to be retrieved. 
allows the stent to be progressively released into the vascu- 
lar lumen (Fig. 1). 
Protocol. Angioplasty was performed according to cur- 
rent practice and all stents were implanted by the same 
operator as previously described (8). After intravenous 
administration of 10,000 to 15,000 IU of heparin and com- 
pletion of balloon angioplasty, all patients received an addi- 
tional 5,000 IU of heparin just before stent implantation; 
heparin infusion was continued without interruption after 
implantation until oral anticoagulation was effective. A low 
dose (up to 100,000 IU) infusion of urokinase was given 
through the guiding catheter during and immediately after 
the stent implantation. Oral anticoagulant administration, 
begun on the day of implantation, was continued for 3 
months and dosage was adjusted to maintain an international 
normalised ratio for thromboplastin time (INR) of 2.3 or 
more. Also prescribed were nifedipine (30 to 60 mglday), 
aspirin (100 mglday) and dipyridamole (300 to 450 mglday). 
In the last nine cases, sulfinpyrazone (400 to 800 mg/day) 
was added to this regimen. 
Results 
The stented graft stenoses were situated in the body of 
the graft in 13 cases and at its proximal implantation into the 
aorta in 1 case (Table 1). The median luminal diameter 
reduction was 90% (range 75% to 95%) and median stenosis 
length was 5 mm (range 4 to 17) before angioplasty. After 
one or more balloon inflations the median stenosis was 
reduced to 40% (range 5% to 90%). 
Stent implantation. Implantation was successful in all 13 
patients and the target segments could be covered in all 
cases with no appreciable residual stenosis (Fig. 2). During a 
single procedure, seven patients received one stent, four 
patients received two stents in the same graft, one patient 
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Figure 2. Patient 9. Example of graft stenosis and stent implantation. A, 
Graft to the posterolateral branch of the circumflex coronary artery 
before angioplasty, with a stenosis in the body of the graft. B, After 
stenting, the stenosis is no longer visible. C, Without contrast injection, 
the stented segment is easily seen (two 5 x 23 mm stents, slightly 
overlapping). 
received two stents in different grafts and one patient re- 
ceived three stents in one graft. Placement of the stent was 
considered satisfactory for 19 (95%) of 20 devices. In one 
case (Patient 9) a second stent was necessary to completely 
cover the target area, because the first device was implanted 
somewhat proximally because of difficulties with the intro- 
ducing device. Median stent diameter in the unconstrained 
state was 4 mm (range 3 to 6) and median length was 23 mm 
(range 15 to 29). 
Ventricular fibrillation occurred during the procedure in 
one putient because of prolonged ischemia. Prompt return to 
sinus rhythm was achieved with direct current cardioversion 
with no long-term adverse effects. There was one case of 
distal coronary embolization after balloon angioplasty, be- 
fore stent implantation. This led to transient occlusion of a 
retroventricular branch but was without clinical conse- 
quences. 
In-hospital follow-up. The median hospital stay after im- 
plantation was 4 days (range 2 to 10). There were no cases of 
death. coronary bypass surgery or myocardial infarction. 
Serial creatine kinase levels remained within normal limits in 
all cases. One patient required blood transfusion because of 
bleeding from the femoral puncture site after the introducer 
was withdrawn and one patient underwent elective surgery 
for a femoral artery pseudoaneurysm 7 days after stent 
implantation. 
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Figure 3. Patient 2. Example of a new stenosis developing proximal 
to an implanted stent. A, Tight stenosis in saphenous graft to the 
right coronary artery, before angioplasty and stent implantation. B, 
Same graft I1 months after the first stent implantation (4.5 x 20 
mm). An eccentric new proximal lesion is visible, together with a 
moderate stenosis immediately proximal to the stent. C, Follow-up 
angiogram 15 months after implantation of two additional stents 
(each 5 x 22 mm). There are some irregularities both within and 
outside the stented segments, but no significant stenosis or reste- 
nosis. D, Same view as in C, without contrast injection. The three 
stents are easily seen. 
Long-term follow-up. All patients were followed up clin- 
ically for a median of 7 months (range 2 to 26). During this 
period, seven patients remained asymptomatic or in im- 
proved condition without further intervention. Two patients 
required a second stenting procedure: the first for two new 
lesions in the same graft (one immediately proximal to the 
stent and another at some distance proximally from it [Fig. 
3]), and the second for a single new lesion immediately 
proximal to the stented segment. One patient had two further 
stenting procedures, each time for a new stenosis that 
occurred immediately proximal to the previously implanted 
prosthesis. All three patients who required more than one 
stenting procedure were further followed up and shown to 
have a satisfactory clinical response 3, 4 and 15 months, 
respectively, after the last stent implant. Two of them have 
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undergone follow-up angiography 3 and 15 months after the 
last stent implantation: there was no restenosis or new 
stenosis of the graft. 
One patient, aged 72 years, who had undergone coronary 
bypass surgery 16 years previously, died 7 months after stent 
implantation from progressive heart failure. No symptoms or 
signs suggesting acute occlusion of the stented graft had 
developed. He did not undergo follow-up angiography or 
necropsy. 
Follow-up angiography. To date, 10 patients have under- 
gone coronary angiography, a median of 5 months (range 3 to 
26) after stent implantation. Significant restenosis (250% 
mean luminal diameter reduction) within the stented seg- 
ment was observed in two patients (20%). One of them 
developed recurrent stenosis of both stented segments in 
two bypass grafts. One restenosis occurred together with 
marked progression of disease outside the stented segment 
and no further intervention was attempted at that site. The 
restenosis in the other graft was first treated by balloon 
angioplasty with a temporary improvement of symptoms. 
Because of recurrent symptomatic restenosis, percutaneous 
transluminal atherectomy (9) was then performed 6 months 
later within the stented segment with a good immediate 
result (Simpson, personal communication). The second pa- 
tient with restenosis was treated by balloon angioplasty 
alone 4 months after stent implantation, with a good clinical 
and angiographic response (Jean Marco, MD, personal com- 
munication). 
Table 1. Individual Patient Data in 13 Cases 
Three patients, all with disabling angina before stent 
implantation. did not undergo follow-up angiography. One of 
them died and two have remained asymptomatic. If it is 
assumed that the absence of angina corresponds to the 
absence of restenosis and that the patient who died may have 
had a recurrence in one or both stents, the restenosis rates 
would be: 3 (23%) of 13 patients, 4 (29%) of 14 grafts and 4 
or 5 (20% to 25%) of 20 stents. 
Follow-up complications. None of the patients underwent 
repeat coronary bypass surgery. There was one case of 
posttraumatic bleeding associated with anticoagulant and 
antiplatelet therapy. No surgery or blood transfusion was 
necessary, and treatment was not discontinued. 
Discussion 
Clinical results (Table 1). This is the first report of intra- 
vascular stenting for saphenous coronary bypass graft ste- 
nosis. Our data show that, in 13 consecutively selected 
patients with disabling symptoms some of whom had under- 
gone more than one surgical revascularization or previous 
balloon angioplasty procedure with recurrent restenosis, or 
both. satisfactory clinical and angiographic improvement 
could be maintained in most cases. Technically adequate 
implantation was achieved in all. In-hospital complications 
associated with the procedure were infrequent and minor. 
There were no in-hospital deaths and no cases of myocardial 
infarction or need for repeat coronary artery bypass surgery 
Patient Age (yr) & DIAM Length Follow-Up Neu 
No. Gender CABG AP Target NB (mm) (mm) (mo) AP Restenosis Stenoci5 Comment 
I 70M I 
2 51M 2 
3 55M 2 
4 62F I 
5 63M 2 
6 58M I 
7 64M I 
8 72M I 
9 75M I 
IO 66M I 
11 69F I 
12 54M I 
13 64M I 
IV LCX 7 3 
IV RCA I 4.5 
IV LCX t LAD 2 4+4 
IV LCX I 3.5 
III LCX I 3.5 
IV RCA I 4 
UA LCx I 4 
IV RCA 2 4+4 
IS 
10 
23 t I9 
15 0 No 
26 0 No 
12 III Yes (2 x) 
23 II 0 No 
73 7 II No 
23 5 0 No 
‘3 Y 0 - 
23 t 23 7 -- 
III LCX 2 5+5 23 t 23 5 0 No 
IV LAD I 6 12 4 UA Yes 
IV LCX 2 5t5 ?I t 11 5 II No 
II RCA 2 4t4 22 t 22 4 0 No 


























AP = Angina1 symptoms before stenting or at follow-up graded according to the New York Heart Association classification: CABG = number of previous 
coronary artery bypass operations; DIAM = diameter of unconstrained implanted stents: Follow-Up = duration of follow-up: LAD = graft to the left anterior 
descending coronary artery; LCx = graft to the left circumflex coronary artery: Length = length of implanted stents; NB = number of stents implanted in one 
procedure; New Stenosi\ = occurrence of a new stenosis at the stent extremity (see text): RCA = graft to the right coronary artery: Target = location of target 
lesions: UA = unstable angina with transient electrocardiographic changes at rest. 
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during the hospital stay or the follow-up period. One patient 
with poor left ventricular function died of cardiac failure 7 
months after stenting without any event suggesting acute 
graft closure. 
Clinically, after one or more stent procedures, 10 patients 
were in improved condition and 8 of them were asympto- 
matic. Restenosis was observed within the stent in 2 (20%) of 
the 10 patients who underwent follow-up angiography. If the 
presence or absence of restenosis is inferred from the clinical 
data for the remaining three patients, the restenosis rates 
would be 3 (23%) of 13 per patient. 4 (29%) of 14 per graft 
and 4 to 5 (20% to 25%) of 20 per stent. These figures are 
lower than the high restenosis rate, usually >40%, observed 
after balloon angioplasty in the body of saphenous vein 
grafts (4-7,10,11). 
Within-stent restenosis. The first of the two patients with 
within-stent restenoses (Patient 3) was initially treated for 
stenosis in one of his grafts by balloon angioplasty alone, but 
the improvement that ensued was only temporary. Trans- 
luminal atherectomy (8) was then performed with an excel- 
lent immediate result. Further experience and follow-up data 
are obviously needed but, when necessary and technically 
feasible, such an approach appears logical for the removal of 
restenosing tissue from within the stented segment. Patient 
10 was treated by balloon angioplasty alone within the 
stented segment with good immediate angiographic and 
clinical results. Early experience in native coronary arteries 
for the treatment of within-stent restenosis (12) suggests that 
significant improvement of restenosis can be obtained with 
balloon angioplasty, but that recurrent restenosis will prob- 
ably remain a problem in a large proportion of cases. 
New stenosis at stent extremity. A new stenosis in the 
same graft, immediately proximal to the stented segment 
(Fig. 3), developed in three patients (in one of them twice). 
In each case it was a short concentric lesion and could be 
successfully dilated and stented with another device over- 
lapping the previous one. Although these lesions may repre- 
sent progression of graft sclerosis, it is likely that the 
shearing forces exerted at the stent extremities at each 
systole contributed to induce a localized reaction. The 
majority of the grafts treated in this series were diffusely 
atherosclerotic, and our approach was modified as experi- 
ence was gained; whenever possible, we now implant longer 
stents, and often use several overlapping stents implanted 
during a single session when diffuse disease is obvious. This 
procedure has made it possible to successfully treat lesions 
that would otherwise have been poor candidates for balloon 
angioplasty alone. 
Bypass grafts versus native coronary arteries. There are 
several theoretical reasons for thinking that vein grafts may 
constitute a particularly favorable target for stent implanta- 
tion: 1) saphenous vein grafts are usually of a larger caliber 
than native coronary arteries and can accommodate larger 
and longer stents; as a rule, the entire area submitted to the 
barotrauma of balloon angioplasty can be covered with the 
stent. 2) Graft compliance is usually higher than that of 
coronary arteries and vasomotor tone or spasm, or both, are 
absent. Diameter mismatch between stent and recipient 
artery is thus not a problem. 
Reports of stenting in native coronary arteries reveal 
conflicting results. The largest overall clinical experience 
with coronary implants is currently that obtained with the 
stent model used in this series (13-18). Initial success rates 
are excellent, but early thrombosis during the first days after 
implantation can remain a potential problem despite a clear- 
cut learning curve effect (19). Other groups have reported 
less favorable results (20), and this difference could well 
represent the effects of a different and less effective drug 
regimen during the postimplantation period. 
Indications. Patient selection led to stent implantation in 
13 (72%) of 18 procedures for which balloon angioplasty was 
attempted for vein graft lesions during the study period. One 
case was excluded because the lesion could not be crossed 
with the balloon, one because the lesion was a total occlu- 
sion and three because the anatomy was considered unsuit- 
able. Experimental and clinical evidence (8,21) suggests that 
important diameter changes (“funnel shape”) of the recipi- 
ent vessel along the stented segment, small (i.e., ~2.5 mm) 
luminal diameter or poor flow are potential risk factors for 
early stent occlusion. Furthermore, stent implantation is 
probably not desirable when the target lesion is situated at 
the distal anastomosis, and interferes with both anterograde 
and retrograde flow to the recipient vessel. 
Although some candidates for balloon angioplasty in 
bypass grafts were thought unsuitable for stenting, some of 
the patients who did receive a stent were poor candidates for 
balloon angioplasty alone, because of several previous re- 
currences after balloon dilation. Stent implantation ,also 
made it possible to treat old grafts with diffuse disease 
without added complications. This may be because stenting 
improves initial rheology by smoothing the endoluminal 
surface (17) and also because it probably prevents emboli- 
zation of friable atherosclerotic material. 
All patients in our series underwent graft stenting at least 
1 year (median 4 years, range 1 to 16) after their last 
coronary bypass operation. The lesions were thus likely to 
be due to graft atherosclerosis in most cases (22,23), com- 
pounded in some with postangioplasty restenosis. It remains 
to be seen whether stenting is equally effective for the early 
focal fibrointimal hyperplasia sometimes observed in grafts 
during the first months after surgery (22,24). 
Conclusions. These initial data are encouraging and sug- 
gest that stenting may offer an alternative treatment to 
selected patients who suffer from recurrent angina with graft 
stenosis after surgical coronary revascularization. However, 
further work needs to be done to assess outcome over a 
longer period of time and to better understand the complex 
interactions between stent and recipient vessel. Modifica- 
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tions in stent design may be necessary to improve results. 
Only then will it be possible to define guidelines and recom- 
mendations for routine clinical use. 
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